Huateng Pharma Introduces Y-Shape PEG NHS
Date
7/23/2024 2:30:39 AM
(MENAFN- Hunan Huateng Pharmaceutical Co Ltd) Changsha, China, July 22, 2024 - Huateng Pharma, a global leader in PEG derivatives and a premier CDMO for APIs and intermediates, is excited to announce the launch of its latest product, Y-Shape PEG NHS. This cutting-edge Succinimidyl Carboxymethyl Ester branched 2ARM PEG offers a revolutionary approach to amine PEGylation, enhancing the modification of proteins and other biologics.
PEGylation, the technique of attaching a PEG derivative to molecules, is crucial for improving the water solubility and biocompatibility of protein drugs. The Y-Shape PEG NHS ester dissolves easily in aqueous buffers, facilitating efficient and effective PEGylation of proteins and biological agents containing lysines. Its advanced structure allows for rapid protein modification, typically completed in under one hour under optimal conditions.
The Y-Shape PEG NHS is particularly valuable in drug development and therapeutic protein formulation. It enhances drug stability, prolongs circulation time, and reduces immunogenicity, making it an essential tool for creating more effective and safer biologic drugs. Additionally, its increased selectivity for sterically accessible amines compared to linear PEG NHS esters ensures more precise and controlled PEGylation.
"Our Y-Shape PEG NHS esters represent a significant leap forward in protein PEGylation technology," said Sonia Lee, Head of Business Development at Huateng Pharma. "This innovation provides researchers and developers with a more efficient and selective tool for optimizing drug formulations, underscoring our dedication to advancing biopharmaceutical technology."
MENAFN23072024006479014044ID1108470030
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.